HC Wainwright Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $60.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective raised by stock analysts at HC Wainwright from $55.00 to $60.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential downside of 1.86% from the stock’s current price.

Other research analysts have also issued reports about the company. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Leerink Partnrs downgraded BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Wolfe Research reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. JPMorgan Chase & Co. upped their price target on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, Tudor Pickering set a $88.00 price objective on shares of BioMarin Pharmaceutical in a research note on Monday, November 3rd. Sixteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $89.70.

BioMarin Pharmaceutical Trading Up 3.1%

Shares of BMRN stock opened at $61.14 on Monday. The stock has a market cap of $11.75 billion, a price-to-earnings ratio of 22.99, a price-to-earnings-growth ratio of 0.99 and a beta of 0.30. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical has a fifty-two week low of $50.76 and a fifty-two week high of $73.51. The firm’s 50 day moving average price is $53.98 and its two-hundred day moving average price is $55.67.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.20). The business had revenue of $776.13 million during the quarter, compared to analyst estimates of $782.42 million. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.BioMarin Pharmaceutical’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, analysts anticipate that BioMarin Pharmaceutical will post 3.15 EPS for the current year.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds have recently made changes to their positions in BMRN. AIA Group Ltd raised its holdings in BioMarin Pharmaceutical by 10.1% in the third quarter. AIA Group Ltd now owns 4,097 shares of the biotechnology company’s stock valued at $222,000 after acquiring an additional 377 shares in the last quarter. Hudson Bay Capital Management LP increased its position in shares of BioMarin Pharmaceutical by 31.8% in the 3rd quarter. Hudson Bay Capital Management LP now owns 693,894 shares of the biotechnology company’s stock worth $37,581,000 after purchasing an additional 167,474 shares during the last quarter. Allworth Financial LP raised its stake in shares of BioMarin Pharmaceutical by 58.9% in the 3rd quarter. Allworth Financial LP now owns 4,201 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,557 shares in the last quarter. IFP Advisors Inc lifted its position in shares of BioMarin Pharmaceutical by 35.7% during the third quarter. IFP Advisors Inc now owns 2,373 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 624 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of BioMarin Pharmaceutical during the third quarter worth about $372,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Truist raised its price target on BMRN to $100 and reiterated a “buy” rating, representing a large upside from current levels — an analyst upgrade that likely helped lift the share price. Truist raises PT to $100
• Positive Sentiment: BioMarin agreed to acquire Amicus Therapeutics for about $4.8 billion, adding two growing rare-disease drugs and a late-stage asset to its pipeline — a deal that expands revenue exposure in rare diseases and was a primary catalyst for bullish analyst commentary. BioMarin to buy Amicus for $4.8B
• Positive Sentiment: Several analysts and outlets grew more bullish on BioMarin following the Amicus deal, framing the transaction as accretive to growth and strategically complementary — supporting upward pressure on the stock. Analysts grow more bullish after Amicus acquisition
• Positive Sentiment: Market commentary and investor write-ups (e.g., Seeking Alpha) are highlighting BioMarin’s broader rare-disease portfolio and potential synergies from the Amicus deal, increasing investor enthusiasm. Seeking Alpha: Amicus buyout sparks enthusiasm
• Neutral Sentiment: Coverage is mixed: a Globe and Mail roundup notes conflicting analyst sentiments across healthcare names, reflecting that not all firms view the deal and prospects identically. Globe and Mail: conflicting analyst sentiments
• Neutral Sentiment: HC Wainwright raised its price target modestly to $60 but kept a “neutral” rating, showing there remains caution among some sell‑side analysts despite the deal. HC Wainwright raises PT to $60 (neutral)
• Neutral Sentiment: General market write‑ups (MSN) summarized the above drivers and the stock move without adding new fundamental detail. MSN: stock is up, what you need to know
• Negative Sentiment: BioMarin announced it has ended development of BMN‑349 (AATD program), a standalone pipeline setback that reduces upside from that asset and underscores program risk in the near term. TipRanks: ends development of BMN-349

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.